Research News and Research

RSS

Kaiser Permanente receives $54 million grant from NIH to conduct health research

As part of the $5 billion in grants announced by President Obama, the National Institutes of Health has granted Kaiser Permanente more than $54 million over two years through the American Recovery and Reinvestment Act to conduct health research on a multitude of critical public and clinical health areas.

14 Oct 2009

Breast tenderness indicates increased cancer risk among women on combination therapy

Women who developed new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy were at significantly higher risk for developing breast cancer than women on the combination therapy who didn't experience such tenderness, according to a new UCLA study.

13 Oct 2009

More employers demand workers prove dependents are eligible for coverage

The Washington Post reports that some employers are pushing ineligible dependents out of health insurance plans. "Call it a sign of the times: A growing number of area employers, including the Commonwealth of Virginia, Johns Hopkins University and the Navy Federal Credit Union, are cracking down on workers who enroll ex-spouses, over-age children, grandchildren and others not entitled to coverage under their health plan.

13 Oct 2009

Prescription drug ads drive up U.S. health costs

NPR reports on how prescription drug advertising drives up consumer demand, which drives up medical costs. The story, done in partnership with the public radio program, This American Life, is the third in a three-part series about why American health care costs are so high. "Prescription drug spending is the third most expensive cost in the U.S. health care system.

13 Oct 2009

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Dyax Corp. announced today new developments involving drug candidates identified using the Company’s proprietary phage display technology as a result of two deals recently announced by sanofi-aventis.

13 Oct 2009

PhysioNetics receives grant to continue development of 'gripper' for upper-extremity prostheses

A $750,000 Phase II grant from the National Institutes of Health will allow PhysioNetics, LLC to continue its development work on an innovative new “gripper” for upper-extremity prostheses.

13 Oct 2009

Human milk oligosaccharides protect infants against infection

Human milk oligosaccharides - an important ingredient in human breast milk - play a central role in protecting infants against infection. An innovative process developed by Jennewein Biotechnologie GmbH allows for the first time ever the production of these scarce sugar molecules for use as an ingredient in baby food and in additional food products.

13 Oct 2009

Sequella receives Phase 1 SBIR grant for developing SQ641

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.

13 Oct 2009

NIH awards fund to Kaiser Permanente and UCSF for genetic epidemiology research

The Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the University of California, San Francisco (UCSF) have been awarded $24.8 million over two years by the National Institutes of Health (NIH) to create a new resource for studying disease, health, and aging.

13 Oct 2009

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.

13 Oct 2009

SANUWAVE presents findings on extracorporeal shock wave stimulation of osteoprogenitor cells

SANUWAVE, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled “Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells” were presented at the 2009 International Bone-Tissue-Engineering Congress (“Bone-Tec”) in Hannover, Germany, which was held October 9-11, 2009.

13 Oct 2009

Cochlear implant inventor chosen for neuroscience research

Dr. Michael Merzenich, PhD - renowned neuroscientist, university professor, cochlear implant inventor, brain plasticity expert and tech entrepreneur - was formally inducted in the Institute of Medicine (IOM) today in Washington, D.C.

13 Oct 2009

Canadian research finds young adults more willing to donate blood

Youth may not bring wisdom but, according to a new study from Canada, it does bring generosity as young adults are found to be the most likely to donate blood. The research, published in BioMed Central's open access International Journal of Health Geographics, looked at what factors had an impact on donating blood.

13 Oct 2009

First Edition: October 13, 2009

All eyes are watching for the outcome of today's Senate Finance Committee health bill vote. Will the measure pass? How will Sen. Olympia Snowe vote? And what about that insurance industry report?

13 Oct 2009

Sixth annual Medical Student Research Forum highlights latest findings

Members of Qatar's research and medical community recently gathered at Weill Cornell Medical College in Qatar to learn more about research conducted by the college's pre-medical and medical students.

13 Oct 2009

Massive mismanagement leads to catastrophic decline in freshwater biodiversity

The world will miss its agreed target to stem biodiversity loss by next year, according to experts convening in Cape Town for a landmark conference devoted to biodiversity science.

13 Oct 2009

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.

13 Oct 2009

NuGEN Technologies enters NGS applications market

NuGEN Technologies, Inc., an innovator in genomic sample preparation, makes a dramatic entry into the next-generation sequencing (NGS) applications market with the strategic addition of a team of experts in NGS, the opening of a new Seattle research facility, and — by year’s end — the launch of a simplified sample preparation kit capable of working from reduced starting material for next-generation RNA-Seq.

13 Oct 2009

University of Nottingham pioneers new type of MRI scan

People with chronic lung disease and asthma could soon be offered better treatment thanks to a new type of Magnetic Resonance Imaging (MRI) scan being pioneered at The University of Nottingham.

13 Oct 2009

AHA: Americans should reduce their calorie intake to combat obesity and cardiovascular disease

Reaching for that chocolate chip cookie? Think twice. The American Heart Association (AHA) just released the strictest guidelines ever for added sugars, recommending Americans limit their diet to 100 calories (6 teaspoons) for women and 150 calories (nine teaspoons) for men each day.

13 Oct 2009